Journal
JOURNAL OF NEURO-ONCOLOGY
Volume 140, Issue 1, Pages 15-26Publisher
SPRINGER
DOI: 10.1007/s11060-018-2927-0
Keywords
RUNX3; Glioma; beta-Catenin; TCF-4
Categories
Funding
- National High Technology Research
- China National Natural Scientific Fund [81101915]
- Tai' an City Technology Development Project [2017NS0117]
- High Level Training Program of Taishan Medicine University [GCC16]
- China Scholarship Council
Ask authors/readers for more resources
Runt-related transcription factor 3 (RUNX3) exerts a tumor suppressor gene associated with gastric and other cancers, including glioma. However, how its anti-tumor mechanism in functions glioma is unclear. We assayed expression of RUNX3 with a tissue microarray (TMA), frozen cancer tissues and malignant glioma cell lines using immunohistochemistry, qRT-PCR and Western bolt analysis. Cell proliferation, invasion, cell cycle distribution and apoptosis were also examined to confirm the effect of RUNX3 medicated malignant phenotype. TOP/FOP experiment was used to detect the beta-catenin/Tcf-4 transcription activity by RUNX3. Enforced RUNX3 expression inhibited proliferation and invasion, induced cell cycle arrest and promoted apoptosis in vitro and in vivo, Bim siRNA partically reversed the effect of RUNX3-induced apoptosis in LN229 and U87 cells, suggesting a dependent role of Bim-caspase pathway. Moreover, Mechanism investigations revealed that restoration of RUNX3 suppressed beta-catenin/Tcf-4 transcription activity. RUNX3 plays a pivotal role in glioma initiation and progression as a tumor suppressor via attenuation of Wnt signaling, highlighting it as a potential therapeutic target for glioma.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available